as 10-30-2025 4:00pm EST
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
| Founded: | 1979 | Country: |   United States  | 
| Employees: | N/A | City: | PLYMOUTH MEETING | 
| Market Cap: | 136.6M | IPO Year: | 1998 | 
| Target Price: | $8.80 | AVG Volume (30 days): | 1.1M | 
| Analyst Decision: | Buy | Number of Analysts: | 5 | 
| Dividend Yield: |  N/A   | Dividend Payout Frequency: | N/A | 
| EPS: | -2.59 | EPS Growth: | N/A | 
| 52 Week Low/High: | $1.30 - $5.80 | Next Earning Date: | 11-10-2025 | 
| Revenue: | $182,337 | Revenue Growth: | -69.19% | 
| Revenue Growth (this year): | -56.86% | Revenue Growth (next year): | 14751.49% | 
INO Breaking Stock News: Dive into INO Ticker-Specific Updates for Smart Investing
 
 PR Newswire
8 days ago
 
 PR Newswire
10 days ago
 
 Simply Wall St.
4 months ago
Thomson Reuters StreetEvents
6 months ago
MT Newswires
6 months ago
 
 GuruFocus.com
6 months ago
 
 Zacks
6 months ago
Associated Press Finance
6 months ago
The information presented on this page, "INO Inovio Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.